Alaska, immunization available to anyone 16 and older who lives or works in the state
US, past 7 days, 2.15 million doses per day
Fists dose, 61 million
Second dose, 32 million
Cases and deaths, CDC data
Possible UK surge
Prof Chris Whitty
Unlocking too quickly, substantial surge while a lot of people are not protected
A lot of people may think this is all over.
It is very easy to forget how quickly things can turn bad
Three weeks to build up immunity
So only the first four priority groups – the over-70s, health and care staff and the extremely clinical vulnerable
Nearly half of hospital admissions have been seen in the under-70s
Most transmission driven by younger people
Therefore, UK strategy will not impact spread for a while yet
Cases, +5,766 (+ 40,600)
Deaths, + 231(+1,329)
Admitted, + 590 (+5,154)
Hospitalised, 9,418 (first time below 10,000 since 25th October)
First dose, 22,592,528
Second dose, 1,181,431
UK is not using a one dose strategy
How do the Pfizer and Oxford AstraZeneca COVID-19 vaccines compare? And how do they affect different people?
March 8, 2021
N = 700,000
Injections, daily health reports
Pfizer vaccine first now, Oxford AstraZeneca as well
Both vaccines cause the body cells to produce the required antigen
Both vaccines induce really high levels of antibodies and T cells
Consistent with phase 3 data
We see around a 70% reduction in mild disease after the vaccine, which is what we would expect. It’s really good news
Systemic side effects
Tiredness, headache, chills
First dose, Oxford AstraZeneca vaccine, 30%
Pfizer vaccine, 10%
Pfizer systemic effects worse if people have had CoViD infection
Pfizer side effects worse after second dose
After effects seem less than phase 3 data
Can’t associate measured immune responses with protection, eg. antibodies may be low, but protection good
Females, younger people, people who had a previous COVID infection, more likely to report after-effects from either vaccine
Not related to level of immunity generated
The FDA has received multiple reports of patients who have required medical support and been hospitalized after self-medicating with ivermectin intended for horses.
Ivermectin is not an anti-viral (a drug for treating viruses).
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Ivermectin proposes many potentials effects to treat a range of diseases
antimicrobial, antiviral, and anti-cancer properties
It is highly effective against many microorganisms including some viruses
In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years
Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2
Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1
In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin
Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. https://doi.org/10.2183/pjab.87.13.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32.
Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6. https://doi.org/10.1208/s12248-007-9000-9.
Family doctors will be allowed to administer vaccine from April
3% currently fully vaccinated, since late December
AZ now used in over 65s
Thomas Mertens, Vaccination committee
Support for the Sputnik V
(European Union officials warn against)
Rolling review, Czech Republic, Hungary and Slovakia.